<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117830</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-108</org_study_id>
    <nct_id>NCT02117830</nct_id>
  </id_info>
  <brief_title>A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects</brief_title>
  <official_title>A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single-site, randomized, double-blinded, double-dummy, placebo- and&#xD;
      positive-controlled, 4-period crossover study to evaluate the effect of two dose levels of&#xD;
      Androxal on cardiac repolarization. Baseline ECGs will be obtained prior to dosing in each&#xD;
      Period and ECGs will be obtained during expected peak plasma concentrations of Androxal and&#xD;
      the positive control.&#xD;
&#xD;
      In each Treatment Period subjects will be admitted to a Clinical Research Unit where study&#xD;
      drug will be administered as three (3) daily single doses. Treatment Periods will be&#xD;
      separated by a washout of at least 7 days between Periods.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The placebo-subtracted change of the QTc interval from Baseline (ΔΔQTc) defined as: the change of QTc from the subject-specific and period-specific Baseline (ΔQTc), less the time-matched placebo value of change of QTc</measure>
    <time_frame>64 days</time_frame>
    <description>The placebo-subtracted change of the QTc interval from Baseline (ΔΔQTc) defined as: the change of QTc from the subject-specific and period-specific Baseline (ΔQTc), less the time-matched placebo value of change of QTc</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Androxal 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Androxal 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>supratherapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>positive control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal 25 mg capsules</intervention_name>
    <arm_group_label>Androxal 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal 250 Capsules</intervention_name>
    <arm_group_label>Androxal 250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsules</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg</intervention_name>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Generally healthy males as determined by history and physical examination&#xD;
&#xD;
          2. Between the ages of 18 and 60, inclusive&#xD;
&#xD;
          3. Clinical laboratory test results within the normal reference ranges for the&#xD;
             investigative site or results with acceptable deviations that are judged by the&#xD;
             principal investigator to be not clinically significant&#xD;
&#xD;
          4. Vital signs (after 5 minutes resting in a supine position)&#xD;
&#xD;
               -  Systolic blood pressure (SBP) 90-140 mmHg, and&#xD;
&#xD;
               -  Diastolic blood pressure (DBP) 50-90 mmHg, and&#xD;
&#xD;
               -  Pulse 45-100 bpm Note: subjects with vital signs outside the above ranges may be&#xD;
                  eligible for the study if the Investigator feels that the results are not&#xD;
                  clinically significant and will not impact study conduct.&#xD;
&#xD;
          5. Body mass index (BMI) ≥25 to ≤42 kg/m2 at Screening&#xD;
&#xD;
          6. Are reliable and willing to be available for the duration of the study, abiding by the&#xD;
             policies and procedures of the clinical trials unit&#xD;
&#xD;
          7. Have given written informed consent&#xD;
&#xD;
          8. Subject must be able to speak, read and understand English or Spanish and be willing&#xD;
             and able to provide written informed consent in English or Spanish on an Institutional&#xD;
             Review Board (IRB)-approved form prior to the initiation of any study procedures.&#xD;
             Subject must have signed and dated a written informed consent form (ICF) before&#xD;
             undergoing any study related activities, including discontinuation of any prohibited&#xD;
             medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Repros employee or investigative site personnel and their immediate families&#xD;
&#xD;
          2. Participation in a clinical trial within the past 30 days or receipt of any&#xD;
             investigational agent or study treatment within 30 days or 5 half-lives, whichever is&#xD;
             longer, prior to Screening&#xD;
&#xD;
          3. Known hypersensitivity to Clomid&#xD;
&#xD;
          4. Known allergy to moxifloxacin&#xD;
&#xD;
          5. Abnormal electrocardiogram that, after the option of repeating any such findings, in&#xD;
             the opinion of the Investigator and/or Sponsor may interfere with any aspect of study&#xD;
             conduct or interpretation of results including:&#xD;
&#xD;
               -  an abnormality of cardiac rhythm other than sinus arrhythmia&#xD;
&#xD;
               -  QTcF &gt; 450 msec&#xD;
&#xD;
               -  QTcF &lt; 300 msec&#xD;
&#xD;
               -  PR interval &gt;200 msec&#xD;
&#xD;
               -  QRS &gt; 110 msec&#xD;
&#xD;
               -  abnormal T wave morphology that will impair the ability to measure the QT&#xD;
                  interval reliably&#xD;
&#xD;
          6. History of congenital long QT syndrome or known history of QTc interval prolongation&#xD;
             or family history of congenital long QT syndrome&#xD;
&#xD;
          7. Evidence of significant cardiac disease, for example, arrhythmia or unexplained&#xD;
             syncope within the last year&#xD;
&#xD;
          8. History of myocardial infarction, unstable angina, symptomatic heart failure,&#xD;
             ventricular dysrhythmia,&#xD;
&#xD;
          9. History of thrombophlebitis, thromboembolic disorder or cerebrovascular accident&#xD;
&#xD;
         10. Evidence of significant respiratory or hepatic disease&#xD;
&#xD;
         11. Use of cigarettes or any tobacco product within 2 weeks prior to Screening and while&#xD;
             participating in the study&#xD;
&#xD;
         12. Use of any medications other than acetaminophen or aspirin (prescription or&#xD;
             over-the-counter), herbal tea , energy drinks, supplements, within 5 days of dosing&#xD;
             (prior to first dose of study medications), with the exception of those approved by&#xD;
             the Investigator and Sponsor&#xD;
&#xD;
         13. Use of drugs of abuse and/or positive findings on drug screen&#xD;
&#xD;
         14. Known active infection with HIV or hepatitis B or C.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>To determine</keyword>
  <keyword>effects</keyword>
  <keyword>once</keyword>
  <keyword>daily</keyword>
  <keyword>oral doses</keyword>
  <keyword>Androxal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

